Table 1 Risk of influenza hospitalization following standard-dose vaccine

From: Incremental benefit of high dose compared to standard dose influenza vaccine in reducing hospitalizations

Influenza season

Risk group*

N SD

Events SD

Event rate % (95% CI) **

2022–2023

Total

409,875 (100%)

669

0.163 (0.151–0.176)

Low risk

254,963 (62%)

224

0.088 (0.076–0.100)

Medium-high risk

154,912 (38%)

445

0.287 (0.261–0.314)

2023–2024

Total

385,062 (100%)

706

0.183 (0.170–0.197)

Low risk

233,241 (61%)

254

0.109 (0.096–0.123)

Medium-high risk

151,821 (39%)

452

0.298 (0.271–0.325)

  1. *Risk groups were determined empirically. Medium to high: (1) individuals aged 75 y and above with at least two comorbidities, (2) individuals younger than 75 y with cardiovascular background, and (3) individuals who are home-bounded.
  2. **95% CI was based on binomial distribution.
Back to article page